Clinical Trial Update: Ioflupane I123 (DaTSCAN) and Positron Emission Tomography-computed Tomography Fludeoxyglucose (PET-CT FDG) to Assess Brain Function of Parkinson Patients' First Degree Relatives

View source ↗

Summary

A clinical trial update describes using DaTSCAN (ioflupane I-123) together with FDG-PET imaging to assess brain function in first-degree relatives of Parkinson …

Upgrade for the full analysis, importance score, and drug timeline.

Diseases / indications

• Parkinson Disease

Drugs mentioned

• DaTscan (ioflupane)
• FDG (fluorodeoxyglucose)

Snippet

Sponsor: Tel-Aviv Sourasky Medical Center | Conditions: Parkinson Disease | Status: UNKNOWN